Trial reportAnnals of the American Thoracic Society2026
Clinical and cost effectiveness of pulmonary rehabilitation for people with post-tuberculosis lung disease in Kyrgyzstan: a single-blind randomized controlled trial.
Trial report in Annals of the American Thoracic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Feasibility and Acceptability of Culturally Appropriate Pulmonary Rehabilitation for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka: Randomized Controlled Trial.International journal of chronic obstructive pulmonary disease · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
rationaleTuberculosis (TB) is a major worldwide cause of disability, with TB survivors experiencing a significant and often underrecognized burden, and approximately half going on to develop post-tuberculosis lung disease (PTLD). Pulmonary rehabilitation may offer effective disease management, but there is a lack of evidence in PTLD populations.
objectivesWe aimed to determine the clinical and cost effectiveness of pulmonary rehabilitation for adults living with PTLD in Kyrgyzstan.
methodsA single-blind randomized controlled trial, conducted March 2021 to June 2022 in Bishkek, Kyrgyzstan, compared supervised pulmonary rehabilitation to usual care for adults living with PTLD. Participants were randomized (1:1) to receive either usual care (control) or culturally adapted pulmonary rehabilitation (intervention), comprising individually prescribed and tailored exercise and self-management education. The primary outcome was change in maximal exercise capacity, measured by the incremental shuttle walking test (ISWT), from baseline to the end of 6 weeks of pulmonary rehabilitation, analyzed by intention-to-treat analysis. Secondary outcomes included health-related quality of life (HRQoL) and cost-effectiveness analysis.
resultsOne hundred fourteen participants (mean ± SD, 43.3 ± 15.2 years; 57% male) received either supervised pulmonary rehabilitation or usual care. Compared with the control group, changes in exercise capacity and HRQoL from baseline were significantly greater in the intervention group (ISWT: 123.0 m [95% CI, 81.2-164.8 m], P <.001; EQ-5D-5L Visual Analogue Scale: 20.2 [95% CI 15.5-24.9], P <.0001). The intervention group saw a significant increase in quality-adjusted life-years (QALYs) over the control group (0.2 [95% CI, 0.1-0.2]). We calculated a total program cost of US$5686.5 (US$95 per patient who received pulmonary rehabilitation), giving a program cost, after adjusting for purchasing power, of US$2143.2 per QALY (95% CI, $1621.9-$2663.9).
conclusionsIn adults with PTLD in Kyrgyzstan, a culturally adapted pulmonary rehabilitation program significantly improved exercise capacity and HRQoL compared with usual care and was both clinically and cost effective.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.